On August 1, the US Food and Drug Administration (FDA) granted full approval to an isocitrate dehydrogenase 2 (IDH2) enzyme inhibitor to treat relapsed or refractory acute myelogenous leukemia (AML)…

Click here  to original publication.

Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 10 OCTOBER 2017